ANCON Technologies’ NBT product to be trialled by NHS in autumn
The NHS will trial ANCON Technologies’ innovative Nanoparticle Biomarker Tagging [NBT] breath test at two hospitals in the autumn, in order to detect a number of diseases including cancer, dementia and tuberculosis.
ANCON Technologies, a British-US technology development firm with its UK headquarters in Kent, featured as a best practice representative in the 2018 Parliamentary Review. We spoke to Group CEO Dr. Robert Muir, CEO of Medical Wesley Baker, head of IP Dr. Boris Gorbunov and Bing Tian, director of Far East Business Development. ANCON discussed how the NBT is a 'once-in-a-generation technology.'
The directors discussed ANCON’s mission to bring this technology to 'the medical screening and diagnostic market', with the first human trials at two NHS hospitals set to happen just one year later, potentially a huge step toward fulfilling that aim.
In the trials, test subjects will breathe into NBT mouthpiece for one minute before the sample is processed by an on site machine. The information will then be sent to a supercomputer at ANCON’s Kent headquarters, which will determine the diagnosis and send it back to the machine at the hospital within seven minutes.
The NBT will allow for rapid early screening and diagnosis of infectious diseases, such as tuberculosis and influenza, as well as lung cancer, by checking a patient’s breath for chemical biomarkers which suggest the disease is present.
In their article, the directors write, "Nanoparticle Biomarker Tagging [NBT] will have a similar impact in today’s healthcare market as the MRI and x-ray created in the past and will generate very-early-stage screening and diagnosis via a non-invasive breath test.
“This technique uses biomarker disease profiling and the latest artificial intelligence software, so every patient increases the knowledge stored in the cloud database and the screening process becomes ever more accurate.”
ANCON’s lofty ambition is for NBT screening and diagnosis systems to be available in 'every medical clinic hospital, pharmacy and public health setting' in order to provide 'real-time early-stage screening and diagnosis for cancers and other diseases; leading to effective, personalised treatments that will save lives, improve quality of life and reduce the cost of long-term medical care.'
Should the trials go well, the technology may be made available to the public as early as 2021.
The NBT is described as being at 'the cutting edge of innovation in the medical device industry' and resulting in a 'real-time, non-invasive screening detection device that outpaces current technology in many qualities, including costs, sensitivity and portability.'
By seeking out chemicals produced by such diseases, the NBT breath test will be more sensitive and accurate to those currently in use, according to ANCON’s article.
After the news of the NHS trials was announced, Dr Glyn Hiatt-Gipson of ANCON’s medical division said: “This [technology] is more sensitive than the nose of a dog and is powered by artificial intelligence so is constantly evolving.
“My vision is that within a decade patients will be able to breath into this mouthpiece and doctors will be able to diagnose as many as 400 different diseases in just one breath.”